BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9458094)

  • 1. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
    Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
    Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
    Adams GP; Schier R; McCall AM; Simmons HH; Horak EM; Alpaugh RK; Marks JD; Weiner LM
    Cancer Res; 2001 Jun; 61(12):4750-5. PubMed ID: 11406547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
    Adams GP; Tai MS; McCartney JE; Marks JD; Stafford WF; Houston LL; Huston JS; Weiner LM
    Clin Cancer Res; 2006 Mar; 12(5):1599-605. PubMed ID: 16533787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
    Adams GP; Schier R; McCall AM; Crawford RS; Wolf EJ; Weiner LM; Marks JD
    Br J Cancer; 1998 May; 77(9):1405-12. PubMed ID: 9652755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration.
    Adams GP; McCartney JE; Wolf EJ; Eisenberg J; Tai MS; Huston JS; Stafford WF; Bookman MA; Houston LL; Weiner LM
    Cancer Immunol Immunother; 1995 May; 40(5):299-306. PubMed ID: 7600561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.
    Adams GP; McCartney JE; Tai MS; Oppermann H; Huston JS; Stafford WF; Bookman MA; Fand I; Houston LL; Weiner LM
    Cancer Res; 1993 Sep; 53(17):4026-34. PubMed ID: 7689421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
    J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.
    Schier R; Marks JD; Wolf EJ; Apell G; Wong C; McCartney JE; Bookman MA; Huston JS; Houston LL; Weiner LM
    Immunotechnology; 1995 May; 1(1):73-81. PubMed ID: 9373335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating improved single-chain Fv molecules for tumor targeting.
    Adams GP; Schier R
    J Immunol Methods; 1999 Dec; 231(1-2):249-60. PubMed ID: 10648942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
    Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP
    Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
    Adams GP; Shaller CC; Dadachova E; Simmons HH; Horak EM; Tesfaye A; Klein-Szanto AJ; Marks JD; Brechbiel MW; Weiner LM
    Cancer Res; 2004 Sep; 64(17):6200-6. PubMed ID: 15342405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: effects on tissue retention in vivo.
    Huang BC; Davern S; Kennel SJ
    J Immunol Methods; 2006 Jun; 313(1-2):149-60. PubMed ID: 16750217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.
    Willuda J; Honegger A; Waibel R; Schubiger PA; Stahel R; Zangemeister-Wittke U; Plückthun A
    Cancer Res; 1999 Nov; 59(22):5758-67. PubMed ID: 10582696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.